focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,794.50
Bid: 1,794.00
Ask: 1,795.00
Change: -18.00 (-0.99%)
Spread: 1.00 (0.056%)
Open: 1,792.50
High: 1,802.00
Low: 1,792.00
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks end in the red as recession fears mount

Fri, 23rd Jun 2023 16:58

(Alliance News) - Stocks in London closed lower on Friday as weak economic data and the prospect of global interests staying higher for longer put investors in a firmly risk-off mood.

"Up until last week, markets had been operating under the premise that rate hikes were coming to an end, however [US Federal Reserve Chair Jerome] Powell's press conference, along with a more hawkish narrative from the European Central Bank last week, and this week's bigger than expected rate hikes from the Bank of England and Norges Bank suggests higher rates are likely to be with us for a long time," said Michael Hewson, chief market analyst at CMC Markets.

"Consequently, markets are now repricing for just such a scenario, where growth is likely to slow considerably as recession risks increase."

The FTSE 100 index closed down 40.16 points, or 0.5% at 7,461.87 on Friday, ending the week 2.4% lower.

The FTSE 250 ended down 265.64 points, or 1.5%, at 18,062.33 and finished the past five days down 5.1%. The AIM All-Share closed down 6.37 points, or 0.8%, at 767.07 - finishing the week down 3.2%.

The Cboe UK 100 ended down 0.5% at 744.19, the Cboe UK 250 closed down 1.6% at 15,814.50, and the Cboe Small Companies ended down 0.6% at 12990.78.

Growth in the UK's private sector was slower than expected in June, according to preliminary survey data, as the gulf between manufacturing and services continued to widen.

The latest S&P Global/CIPS UK flash composite PMI fell to 52.8 points in June, from 54.0 in May. The market had been expecting only a slight decline to 53.6, according to FXStreet-cited consensus.

The flash services PMI fell to 53.7 from 55.2, lower compared to market forecasts of 54.8. Meanwhile, the contraction in manufacturing worsened, with the PMI slipping to 46.2 from 47.1, which was also below forecasts of 46.8.

The sluggish private sector growth has put the risk of an economic downturn in the UK at the forefront of investors' minds. Swissquote senior analyst Ipek Ozkardeskaya was more pessimistic: "At this point, it would be a miracle for Britain to avoid recession."

On Thursday, the Bank of England surprised with a chunkier-than-expected 50 basis point interest rate hike. It took bank rate to 5.00% from 4.50%.

The pound was quoted at USD1.2709 at the London equities close Friday, down from USD1.2741 at the close on Thursday.

Prior to the BoE's hike on Thursday, sterling had traded at USD1.2781 and had spiked as high as USD1.2830 in the immediate wake of the decision. Sterling has since lost all these gains.

In London, GSK was the top blue-chip performer at the close on Friday, finishing 5.0% higher.

The pharmaceutical company said it has reached a confidential settlement with James Goetz, a claimant in Zantac litigation. The case he filed in the California state court, which was set to begin in July, will now be dismissed.

Zantac is the subject of numerous lawsuits, which allegedly link the heartburn drug with cancer.

GSK said the settlement reflects its desire to avoid a protracted legal fight. It added that it does not admit any liability and will continue to "vigorously defend itself" in Zantac cases.

"News pharmaceutical giant GSK has settled a case in California alleging its Zantac heartburn medication caused cancer, while crucially admitting no liability, is not a full stop on the saga but is the latest punctuation point in what shareholders will hope is its final stanza," said AJ Bell's Hewson.

"Once the world's best-selling drug, there have been a series of lawsuits brought in the US implying a link between Zantac and cancer but, so far, GSK has been able to navigate its way through these choppy waters."

Haleon, which also has exposure to Zantac litigation, finished 0.6% higher.

Ocado ended as the FTSE 100's worst-performing stock on Friday. It finished 6.0% lower, slipping back from its 32% gain on Thursday which was driven by chatter that the online retailer and warehouse technology provider is the object of takeover interest.

In the FTSE 250, Volution was the index's best performer, finishing 2.90% higher after it announced it had completed its acquisition of designer, manufacturer and supplier of residential ventilation systems, I-Vent.

"We are delighted to have completed this earnings accretive transaction, and look forward to welcoming our new colleagues in I-Vent to the group. The acquisition gives the group access to fast-growing new markets in Slovenia and Croatia," said Chief Executive Ronnie George.

Elsewhere in London, EnQuest lost 6.4%.

The London-based oil and gas producer with assets in the UK and Malaysia's stock was under pressure as the price of a barrel of Brent oil fell to USD73.71 at the London equities close on Friday, from USD74.22 late Thursday.

"Pressure on oil prices in recent weeks has been largely supply-driven. Now, oil markets are struggling against an even more hawkish monetary policy backdrop than anticipated, which could hurt demand," explains SPI Asset Management's Stephen Innes.

On AIM, Hotel Chocolat plunged 17% after the high-street chocolatier warned it expects to swing to an underlying marginal pretax loss in its financial year ending July 2, defying market expectations of GBP300,000 in underlying pretax profit.

In financial 2024, it expects sales and underlying profit before tax to be lower than market expectations, due to weak consumer sentiment and continuing inflationary pressures.

In European equities on Friday, the CAC 40 in Paris ended down 0.6%, while the DAX 40 in Frankfurt ended down 1.0%.

Stocks in New York were lower at the London equities close, with the Dow Jones Industrial Average down 0.5%, the S&P 500 index down 0.7%, and the Nasdaq Composite down 1.0%.

The euro stood at USD1.0888 at the European equities close on Friday, sharply lower against USD1.0953 at the same time on Thursday. Against the yen, the dollar was trading at JPY143.73, higher compared to JPY142.86 late Thursday.

"The words from the chairman of the Fed, alongside the BoE's assertiveness, show that central banks aren't yet done with monetary tightening, in a dynamic that highlights the risks of an economic contraction. Against this background, there may be scope for further US dollar gains," said Ricardo Evangelista, senior analyst at ActivTrades.

Gold was quoted at USD1,922.24 an ounce, higher against USD1,913.60 at the close on Thursday.

In Monday's UK corporate calendar, there are half-year results from Rio Tinto and Carnival, as well as a trading statement from Associated British Foods.

The economic calendar next week has US house price data on Tuesday, US GDP figures on Thursday, and a flash inflation reading for the EU on Friday.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more
15 Feb 2024 14:44

UK dividends calendar - next 7 days

Friday 16 February 
JPMorgan Asia Growth & Income PLCdividend payment date
JPMorgan Japan Small Cap Growth & Income PLCdividend payment date
Murray International Trust PLCdividend payment date
Premier Miton Group PLCdividend payment date
Schroder Oriental Income Funddividend payment date
Solid State PLCdividend payment date
Monday 19 February 
no events scheduled 
Tuesday 20 February 
Invesco Bond Income Plus Ltd 
Wednesday 21 February 
no events scheduled 
Thursday 22 February 
abrdn Asia Focus PLCex-dividend payment date
Alumasc Group PLCex-dividend payment date
AstraZeneca PLCex-dividend payment date
BlackRock Throgmorton Trust PLCex-dividend payment date
Braemar PLCex-dividend payment date
easyJet PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
Endeavour Mining PLCex-dividend payment date
FRP Advisory Group PLCex-dividend payment date
Gateley Holdings PLCex-dividend payment date
GSK PLCex-dividend payment date
Hercules Site Services PLCex-dividend payment date
Jersey Electricity PLCex-dividend payment date
Land Securities Group PLCex-dividend payment date
Molten Ventures VCT PLCex-dividend payment date
Northern Bear PLCex-dividend payment date
Redrow PLCex-dividend payment date
Samuel Heath & Sons PLCex-dividend payment date
Titon Holdings PLCex-dividend payment date
Unilever PLCex-dividend payment date
Van Elle Holdings PLCex-dividend payment date
Virgin Money UK PLCex-dividend payment date
Witan Investment Trust PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
15 Feb 2024 11:02

Berenberg hikes target price on GSK

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.

Read more
15 Feb 2024 09:45

LONDON BROKER RATINGS: Jefferies cuts Kingfisher but Citi raises

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
15 Feb 2024 08:49

GSK completes USD1.4 billion purchase of respiratory firm Aiolos Bio

(Alliance News) - GSK PLC on Thursday said it has completed the acquisition of Aiolos Bio Ltd, expanding its respiratory portfolio with a potential "best-in-class" asthma treatment.

Read more
13 Feb 2024 16:53

LONDON MARKET CLOSE: Stocks in red amid sticky US inflation data

(Alliance News) - Stock prices in London closed in the red on Tuesday, after a key US inflation reading came in hotter-than-expected.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.